| 4.93 -0.68 (-12.12%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.24 |
1-year : | 7 |
| Resists | First : | 5.34 |
Second : | 6 |
| Pivot price | 5.27  |
|||
| Supports | First : | 4.28 |
Second : | 3.56 |
| MAs | MA(5) : | 5.4 |
MA(20) : | 5.09 |
| MA(100) : | 6.37 |
MA(250) : | 6.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 64.3 |
D(3) : | 76.3 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 9.82 | Low : | 4.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ HELP ] has closed above bottom band by 12.6%. Bollinger Bands are 55.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.63 - 5.66 | 5.66 - 5.68 |
| Low: | 4.79 - 4.82 | 4.82 - 4.85 |
| Close: | 4.88 - 4.93 | 4.93 - 4.97 |
C
Sun, 19 Apr 2026
Cybin Inc. Common Stock (HELP) - Minichart
Sat, 10 Jan 2026
Why Cybin (HELP) Is Down 9.1% After Rebranding To Helus And Relisting On Nasdaq - Yahoo Finance
Tue, 06 Jan 2026
Cybin Inc. (HELP) - Zacks Investment Research
Mon, 05 Jan 2026
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq - Business Wire
Wed, 31 Dec 2025
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - Seeking Alpha
Tue, 30 Dec 2025
Cybin stock falls after launching $100 million ATM program - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 91 (M) |
| Held by Insiders | 5.7 (%) |
| Held by Institutions | 59.6 (%) |
| Shares Short | 3,540 (K) |
| Shares Short P.Month | 3,320 (K) |
| EPS | -4.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32 % |
| Return on Equity (ttm) | -55.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -112 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -1.15 |
| PEG Ratio | 0 |
| Price to Book value | 98.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|